- Home
- GRRR vs DVAX Comparison
GRRR vs DVAX Comparison
Compare GRRR & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRRR
- DVAX
- Stock Information
- Founded
- GRRR 2001
- DVAX 1996
- Country
- GRRR United Kingdom
- DVAX United States
- Employees
- GRRR N/A
- DVAX N/A
- Industry
- GRRR Computer Software: Prepackaged Software
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- GRRR Technology
- DVAX Health Care
- Exchange
- GRRR Nasdaq
- DVAX Nasdaq
- Market Cap
- GRRR 391.9M
- DVAX 1.3B
- IPO Year
- GRRR N/A
- DVAX 2004
- Fundamental
- Price
- GRRR $20.48
- DVAX $9.78
- Analyst Decision
- GRRR Buy
- DVAX Buy
- Analyst Count
- GRRR 1
- DVAX 4
- Target Price
- GRRR $18.00
- DVAX $26.50
- AVG Volume (30 Days)
- GRRR 1.3M
- DVAX 2.0M
- Earning Date
- GRRR 08-14-2025
- DVAX 11-06-2025
- Dividend Yield
- GRRR N/A
- DVAX N/A
- EPS Growth
- GRRR N/A
- DVAX N/A
- EPS
- GRRR N/A
- DVAX N/A
- Revenue
- GRRR $93,325,178.00
- DVAX $316,268,000.00
- Revenue This Year
- GRRR $38.13
- DVAX $23.23
- Revenue Next Year
- GRRR $28.55
- DVAX $16.57
- P/E Ratio
- GRRR N/A
- DVAX N/A
- Revenue Growth
- GRRR 18.22
- DVAX 26.66
- 52 Week Low
- GRRR $3.33
- DVAX $9.20
- 52 Week High
- GRRR $44.15
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- GRRR 69.79
- DVAX 44.09
- Support Level
- GRRR $17.22
- DVAX $9.20
- Resistance Level
- GRRR $21.48
- DVAX $9.94
- Average True Range (ATR)
- GRRR 1.11
- DVAX 0.31
- MACD
- GRRR 0.37
- DVAX -0.01
- Stochastic Oscillator
- GRRR 89.69
- DVAX 51.82
About GRRR Gorilla Technology Group Inc.
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.